Skip to Content

What type of drug is Libtayo?

Medically reviewed by Last updated on Mar 24, 2019.

Official Answer


Libtayo (cemiplimab-rwlc) is classified as a programmed death receptor-1 (PD-1) blocking antibody (also called an immune checkpoint inhibitor).

Libtayo from Sanofi and Regeneron is approved for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation. Libtayo is the first FDA approval of a drug specifically for advanced CSCC.

To learn more about Libtayo and other immune checkpoint inhibitors, review the following slideshow:

Related Medical Questions

Drug Information

Related Support Groups